Comparison of the Risk of Cancer Between Patients With Type 2 Diabetes Exposed to Dapagliflozin and Those Exposed to Other Antidiabetic Treatments

First published 15/01/2016

Last updated 05/01/2026

EU PAS number:

EUPAS12116

Study

Finalised

Documents

Study protocol

Initial protocol

DAPA Protocol MB102118_Cancer_ 27June 2014_final_redacted

English (852.94 KB - PDF) View document

Updated protocol

Dapa Cancer Protocol MB102118__v3.1_06Jun2023_final_signed_Redacted

First published: 22/02/2024

English (6.69 MB - PDF) View document

Study results

Study report

Other information

Study, other information

Dapa Cancer Protocol MB102118_28Feb2017_redacted

English (899.62 KB - PDF) View document

Publications

Study publications

Secondary tabs